Novel Cambinol Analogs as Sirtuin Inhibitors: Synthesis, Biological Evaluation, and Rationalization of Activity
journal contributionposted on 14.05.2009, 00:00 by Federico Medda, Rupert J. M. Russell, Maureen Higgins, Anna R. McCarthy, Johanna Campbell, Alexandra M. Z. Slawin, David P. Lane, Sonia Lain, Nicholas J. Westwood
The tenovins and cambinol are two classes of sirtuin inhibitor that exhibit antitumor activity in preclinical models. This report describes modifications to the core structure of cambinol, in particular by incorporation of substitutents at the N1-position, which lead to increased potency and modified selectivity. These improvements have been rationalized using molecular modeling techniques. The expected functional selectivity in cells was also observed for both a SIRT1 and a SIRT2 selective analog.